said an economic review of its Biscathorpe project located within Lincolnshire licence, PED253, has confirmed the project to be ‘financially robust with break-even economics at US$18.07 bbl’.
The group unveiled findings confirming the value of its principal target at Biscathorpe, Westphalian which is estimated to be potentially worth around £55.6m.
Meanwhile, Union’s secondary Dinantian Carbonate target was labelled as a ‘commercially viable play’ with 24.3m barrels.
Biscathorpe is located within the proven hydrocarbon fairway of the Humber Basin, on-trend with the Saltfleetby gasfield and Keddington oilfield.
Shares in Union Jack Oil were trading flat at 0.095p during Monday morning trading.
The company added that drill targets are accessible for a side-track from the previously suspended Biscathorpe-2 well.
"We are highly encouraged by the conclusions of this detailed review of data in respect of Biscathorpe, particularly given the attractive resource volumes and values associated with the Westphalian and Dinantian targets,” said David Bramhill, Executive Chairman of Union Jack Oil.
Union Jack believes that PEDL253 remains one of the UK's largest onshore un-appraised conventional hydrocarbon licences.
Bramhill said extensive technical analysis and APT conclusions confirming the likely presence of good quality oil had “materially upgraded” the resource potential and economic value of the project.
In early March, Union Jack Oil acquired an additional 35% stake in the producing Keddington oil field from Terrain Energy Limited taking its total economic interest in the asset to 55%
Follow News & Updates fromhere:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - London stocks were well into positive territory at the close on Friday, with banks pacing the advance after well-received results from Barclays, as investors shrugged off news that the UK's economic recovery was stalling.
Gunsynd, an investment firm operating within the natural resources sector, announced that it has invested C$0.25 million (around £0.146 million) into precious metals royalty and streaming company Empress Royalty Corp. The group said the move complements existing investments in the precious metals sector, adding new commodity exposure to silver.
Clinical stage drug development firm, Evgen Pharma, has been given the green light to kick-start its STAR trial which will investigate whether its lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.
Braveheart Investment Group, the AIM-listed investment firm, said its investee company, Pharm2Farm ("P2F"), will launch the sale of a new antiviral face mask that has a ‘kill rate’ of over 90% for up to 7 hours for COVID-19 by the end of the year.
London-listed Sensyne Health, the UK-based clinical AI company, announced that it has signed a research collaboration agreement with US pharmaceutical company Bristol Myers Squibb ("BMS"), marking its fourth successive partnership with a major pharma company.